- Home
- EVC vs GALT Comparison
EVC vs GALT Comparison
Compare EVC & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVC
- GALT
- Stock Information
- Founded
- EVC 1996
- GALT 2000
- Country
- EVC United States
- GALT United States
- Employees
- EVC N/A
- GALT N/A
- Industry
- EVC Broadcasting
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- EVC Industrials
- GALT Health Care
- Exchange
- EVC Nasdaq
- GALT Nasdaq
- Market Cap
- EVC 226.5M
- GALT 232.3M
- IPO Year
- EVC 2000
- GALT N/A
- Fundamental
- Price
- EVC $2.13
- GALT $5.17
- Analyst Decision
- EVC
- GALT Strong Buy
- Analyst Count
- EVC 0
- GALT 3
- Target Price
- EVC N/A
- GALT $6.00
- AVG Volume (30 Days)
- EVC 144.0K
- GALT 243.0K
- Earning Date
- EVC 11-05-2025
- GALT 11-12-2025
- Dividend Yield
- EVC 9.52%
- GALT N/A
- EPS Growth
- EVC N/A
- GALT N/A
- EPS
- EVC N/A
- GALT N/A
- Revenue
- EVC $396,704,000.00
- GALT N/A
- Revenue This Year
- EVC $64.06
- GALT N/A
- Revenue Next Year
- EVC N/A
- GALT N/A
- P/E Ratio
- EVC N/A
- GALT N/A
- Revenue Growth
- EVC 25.34
- GALT N/A
- 52 Week Low
- EVC $1.58
- GALT $0.73
- 52 Week High
- EVC $2.73
- GALT $6.55
- Technical
- Relative Strength Index (RSI)
- EVC 33.90
- GALT 68.00
- Support Level
- EVC $2.07
- GALT $4.56
- Resistance Level
- EVC $2.24
- GALT $5.35
- Average True Range (ATR)
- EVC 0.07
- GALT 0.28
- MACD
- EVC -0.02
- GALT 0.03
- Stochastic Oscillator
- EVC 13.82
- GALT 79.40
About EVC Entravision Communications Corporation
Entravision Communications Corp owns and operates Spanish language television and radio stations in the United States. The Company also owns and operates a smaller group of television stations that broadcast English language programming and has operations that provide programmatic advertising technology and services. The Company has organized its operations into two reportable segments. Its media segment includes its television, radio, and digital marketing operations. Its advertising and technology services segment provides programmatic advertising and technology services. The company generates the majority of its revenue from the Media segment. Geographically, the company generates the majority of its revenue from the United States.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.